South Korea · Delayed Price · Currency is KRW Kainos Medicine Company Description
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally.
The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS.
It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells.
In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug.
The company was founded in 2007 and is headquartered in Seongnam-si, South Korea.
| Country | South Korea |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Ki-Sub Lee |
Contact Details
Address: Building A, Korea Bio-Park Seongnam-si, 13488 South Korea | |
| Phone | 82 2 567 7419 |
| Website | kainosmedicine.com |
Stock Details
| Ticker Symbol | 284620 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ki-Sub Lee | Chief Executive Officer |